Skip to NavigationSkip to content

heart disease

Galectin-3: The protein paving new treatment avenues

Published on 01/11/18 at 11:14am

Matthew Blakeley, LADI-III Beamline Scientist at Institut Laue-Langevin (ILL) and Derek Logan, Associate Professor in Structural Biology at Lund University, discuss galectin-3 and its link to diabetes, heart disease and breast cancer, and how it could lead us to new therapies.

Can you provide a bit of background on galectins and why our understanding of them is important in the discovery/design of new treatments?

"Triple pill" blood pressure combo proves more effective, safe than standard care

A “triple pill” combining three established and effective drugs at low dosage levels could prove much more effective in treating high blood pressure than any of its constituent elements alone, according to research conducted by the George Institute for Global Health, an independent medical institution with branches in the UK, Australia, and India.

“It's estimated more than a billion people globally suffer from high blood pressure, with the vast majority having poorly controlled blood pressure,” said lead study author Dr Ruth Webster, Head of Research Programs at the George Institute

EMA issues global recall of heart drugs over cancer risk contamination

Several drugs designed for the treatment of high blood pressure and heart conditions have been recalled across Europe over fears they could contain a probable carcinogen and thus pose an increased risk of cancer in users, it has emerged.

New AI system for lung cancer and heart disease could save NHS billions

A team of researchers at Oxford’s John Radcliffe Hospital have unveiled a new artificial intelligence system which they claim could cut operational costs by billions of pounds at NHS hospitals by helping to detect heart disease and lung cancer early, even suggesting the health service could benefit from the platform for free by as early as the summer.

Novartis targets specific patient population with strong Ilaris Phase 3 data

Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific subgroup of the trial’s patient population – a subgroup which the Swiss drugmaker is now looking to target with the drug.

MSD scores trial success in reducing cardiovascular risk

New data on MSD’s anacetrapib has revealed that the drug was able to reduce risk of the risk of major coronary events by 9% compared to placebo in a study of 30,449 patients suffering atherosclerotic vascular disease and receiving LDL-C lowering treatment with atorvastatin.

Where will the next cardiovascular breakthrough come from?

Published on 17/08/17 at 11:03am

British Heart Foundation’s Jennifer Mitchell, Research Communications Officer, explains the work they are doing to find the next breakthrough treatment for cardiovascular disease.

Over the past 50 years the number of people in the UK dying of cardiovascular disease each year has halved. This reduction in deaths can largely be attributed to an increase in society’s understanding of heart disease and the improvements in lifestyle and treatments that this knowledge has led to.

Mending broken hearts with an injectable patch

IMAGE: Miles Montgomery and Rick Lu

A team of researchers from the University of Toronto have confronted a problem that had previously had no solution – how to repair heart tissue without open-heart surgery.

The reason it is necessary to avoid open-heart surgery is because of the stress it places on the body and, in particular, the heart. The latest innovation could see an injectable patch inserted into the heart without the need for invasive surgery.

Battling misinformation on the world’s biggest killer

Published on 14/08/17 at 12:37pm

Simon Williams, Head of Communications and Policy at Heart UK, discusses the threat posed by cholesterol in the development of cardiovascular conditions, and how statins are key to solving the problem, if the treatment could only escape unwarranted criticism.

Heart failure mortality rates fall across England and Wales, national audit finds

Great news in the cardiovascular space as results from the National Heart Failure Audit indicate that better treatment has led to hundreds of lives being saved, with the mortality rate associated with heart failure in England and Wales dropping to 8.9% in 2015-16 from 9.6% the previous year.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches